Our Research Approach
We integrate cutting-edge technologies in viral engineering, T cell engineering, and antibody engineering to develop next-generation therapeutics for cancer, autoimmune diseases, and organ rejection.
Viral Engineering
We engineer viral vectors — including lentiviral and adeno-associated virus (AAV) systems — as precision tools for delivering genetic payloads into immune cells and target tissues. Our goal is to harness the natural efficiency of viruses while maximizing safety and specificity.
These platforms serve as the backbone for our broader therapeutic programs, enabling durable gene expression in cells.
T Cell Engineering
We develop next-generation engineered T cells — including CAR-T and TCR-T platforms — designed to recognize and eliminate diseased cells with high precision. Our work spans the full spectrum from receptor design to in vivo persistence and safety.
Beyond cancer, we are actively engineering T cells to restore immune balance in autoimmune diseases and to induce tolerance, addressing organ rejection as a critical unmet need. By reprogramming T cell identity and function, we aim to build truly versatile cellular medicines.
Antibody Engineering
We engineer novel antibody formats — including bispecific antibodies and multispecific constructs — to redirect immune responses with unprecedented precision. Our antibodies are designed to engage multiple targets simultaneously, bridging immune effector cells to diseased tissue across diverse therapeutic contexts.